Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01124006 · ClinicalTrials.gov registry record · Phase 2
A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration
A Phase 2 study, sponsored by DePuy Spine.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01124006 is a Phase 2 study that has completed, run by DePuy Spine. The registered enrollment target is 24 participants.
The verdict
NCT01124006, a Phase 2 study, has completed, sponsored by DePuy Spine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Study to show the safety and tolerability of Intradiscal rhGDF-5 in subjects with early lumbar disc degeneration
Interventions
- DRUG Intradiscal rhGDF-5
- OTHER Water for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01124006
The ClinicalTrials.gov registry entry for NCT01124006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DePuy Spine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intradiscal rhGDF-5 is the first listed.
NCT01124006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01124006 about?
NCT01124006 is a clinical study titled "A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration". Study to show the safety and tolerability of Intradiscal rhGDF-5 in subjects with early lumbar disc degeneration
What is the current status of trial NCT01124006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01124006?
The interventions under investigation include: Intradiscal rhGDF-5 (DRUG), Water for injection (OTHER).
Who is sponsoring clinical trial NCT01124006?
This trial is sponsored by DePuy Spine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.